- 5 June 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 106 (17) , 1594-1599
Abstract
Background: Despite a tremendous increase in the number of orthopaedic devices authorized by the U.S. Food and Drug Administration (FDA), novel devices designed specifically for the pediatric population remain sparse. Surgeons frequently repurpose adult implants for “off-label” use in pediatric patients, with both legal and technical ramifications. This study seeks to objectively quantify and characterize the nature of pediatric device innovation over time. Methods: The FDA employs 4 pathways for assessing safety and effectiveness of novel devices prior to authorization. Perceived device risk and novelty determine the pathway. Orthopaedic devices were identified from the FDA’s online database. All devices approved since inception via the Humanitarian Device Exemption, Pre-Market Approval, and De Novo regulatory pathways were included and grouped as “highly innovative.” Because of their number and the rapidity of their development, the evaluation of 510(k) devices was limited to those cleared from January 1, 2018, to December 31, 2022. Such 510(k) devices make up ∼97% of devices and by definition are less risky and less novel. Approval statements were assessed for pediatric indications within the approved labeling. As a secondary analysis, the impact of company size on developing a product with a pediatric indication was analyzed. Results: Of the 1,925 devices cleared via the 510(k) pathway, 9 (0.5%) were designed exclusively for pediatrics and 160 (8.3%) included pediatric indications. Five of the 9 pediatrics-only devices were for spine and 4 were for trauma indications. Of the 97 highly innovative devices, only 2 (2%) were exclusively pediatric and another 2 (2%) included pediatric indications. The 2 pediatrics-only devices were for the spine. Large and medium-sized companies were 1.9 times and 1.6 times more likely to bring to market a device with pediatric indications than a small company, respectively. Conclusions: Innovation for pediatric orthopaedic devices lags substantially behind that for adult orthopaedic devices. These findings are consistent with clinical experience and the common practice of modifying adult implants for “off-label” use in pediatric patients. Despite long-standing efforts to stimulate innovation for this vulnerable population, our results suggest little progress.Keywords
This publication has 11 references indexed in Scilit:
- Risk of Recall Associated With Modifications to High-risk Medical Devices Approved Through US Food and Drug Administration SupplementsJAMA Network Open, 2023
- Trends in Orthopedic Device Innovation: An Analysis of 510(k) Clearances and Premarket Approvals From 2000 to 2019Orthopedics, 2023
- High-risk Therapeutic Devices Approved by the US Food and Drug Administration for Use in Children and Adolescents From 2016 to 2021JAMA Pediatrics, 2022
- Estimated Cost of Developing a Therapeutic Complex Medical Device in the USJAMA Network Open, 2022
- Pediatric Medical Device Development and Regulation: Current State, Barriers, and OpportunitiesPediatrics, 2022
- Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age IndicationsJAMA Network Open, 2021
- The Scarcity of Approved Pediatric High-Risk Medical DevicesJAMA Network Open, 2021
- Off-Label Use of Medical Devices in ChildrenPediatrics, 2017
- Postmarketing Trials and Pediatric Device ApprovalsPediatrics, 2014
- Off-Label Use of Pediatric Orthopaedic Devices: Important Issues for the FutureJournal of Bone and Joint Surgery, 2014